BioAge Labs, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Sale $1,001 - $15,000 |
Jul 13, 2016 | Jun 9, 2016 | Filing ↗ |
Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 20, 2014 | Oct 9, 2014 | Filing ↗ |
Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 20, 2014 | Oct 10, 2014 | Filing ↗ |
Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $15,001 - $50,000 |
Aug 17, 2014 | Jul 24, 2014 | Filing ↗ |
Whale Activity
- Increased52
- New44
- Held17
- Decreased44
- Closed34
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 3.5M | $25.1M | increased |
| a16z Capital Management, L.L.C. | 3.2M | $22.9M | held |
| Sofinnova Investments, Inc. | 2.3M | $16.3M | held |
| Cormorant Asset Management, LP | 2.2M | $15.9M | decreased |
| MPM BioImpact LLC | 1.9M | $13.2M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $11.5M | increased |
| STATE STREET CORP | 1.3M | $9.6M | increased |
| Octagon Capital Advisors LP | 1.3M | $9.2M | decreased |
| D. E. Shaw & Co., Inc. | 1.2M | $8.2M | increased |
| Polar Capital Holdings Plc | 1.1M | $7.6M | decreased |
| BRAIDWELL LP | 1.0M | $7.3M | held |
| GEODE CAPITAL MANAGEMENT, LLC | 921.5K | $6.5M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Barton ShanePrincipal Accounting Officer | Sale | −20.2K | $25.19 | $509K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +7,861 | $4.38 | $34K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +4,065 | $4.30 | $17K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +4,000 | $8.39 | $34K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +4,290 | $10.85 | $47K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Sale | −42.4K | $25.21 | $1.1M | Jun 29, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +14.2K | $4.38 | $62K | Jun 29, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +8,958 | $4.30 | $39K | Jun 29, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +7,261 | $8.39 | $61K | Jun 29, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Option exercise | +9,301 | $10.85 | $101K | Jun 29, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | Apr 23, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −8,820 | $17.81 | $157K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +3,383 | $6.57 | $22K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +5,437 | $4.11 | $22K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −7,433 | $20.30 | $151K | Mar 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +2,000 | $6.57 | $13K | Mar 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +5,433 | $4.11 | $22K | Mar 2, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | Mar 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −7,433 | $18.75 | $139K | Feb 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +2,000 | $6.57 | $13K | Feb 2, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $28.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 915.6K | $22.4M | 0.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 368.0K | $9.0M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 296.8K | $7.3M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 262.2K | $6.4M | 1.50% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 223.3K | $5.5M | 0.06% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF Fidelity Covington Trust | 171.4K | $4.2M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 385.0K | $3.5M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 118.1K | $2.9M | 0.19% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF iShares Trust | 82.9K | $2.0M | 0.18% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BIOA's shares (CUSIP 09077V100), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Bihua ChenSCHEDULE 13G/A · passive (13G) · 2.2M shares4.9%
Nov 16, 2026 · ↗ - Cormorant Asset Management, LPSCHEDULE 13G/A · passive (13G) · 2.2M shares4.9%
Nov 16, 2026 · ↗ - Bihua ChenSCHEDULE 13G/A · passive (13G) · 2.4M shares5.4%
Aug 14, 2026 · ↗ - Cormorant Asset Management, LPSCHEDULE 13G/A · passive (13G) · 2.4M shares5.4%
Aug 14, 2026 · ↗ - Vinod KhoslaSCHEDULE 13G/A · passive (13G) · 1.8M shares4.0%
May 15, 2026 · ↗ - VK Services, LLCSCHEDULE 13G/A · passive (13G) · 1.8M shares4.0%
May 15, 2026 · ↗ - Khosla Ventures Opportunity Associates I, LLCSCHEDULE 13G/A · passive (13G) · 1.4M shares3.1%
May 15, 2026 · ↗ - Khosla Ventures Associates VI, LLCSCHEDULE 13G/A · passive (13G) · 437.2K shares1.0%
May 15, 2026 · ↗ - Khosla Ventures Opportunity I, LPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.1%
May 15, 2026 · ↗ - Khosla Ventures VI, LPSCHEDULE 13G/A · passive (13G) · 437.2K shares1.0%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming BioAge Labs, Inc. as the client.
Government Contracts
No federal contract awards found for BioAge Labs, Inc..
U.S. Patents
No USPTO patent applications found for BioAge Labs, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $9.0M | $0 | n/a |
| Operating income | -$92.8M | -$78.2M | -$48.4M |
| Net income | -$80.6M | -$71.1M | -$63.9M |
| Diluted EPS | -$2.24 | -$6.63 | -$38.17 |
| Operating cash flow | -$81.6M | -$51.5M | -$37.4M |
| Cash and equivalents | $188.9M | $354.3M | $21.6M |
| Total assets | $294.9M | $358.2M | $25.9M |
| Total liabilities | $22.8M | $35.1M | $66.6M |
| Shareholders' equity | $272.1M | $323.1M | -$173.4M |
As BioAge Labs, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 24, 2026 ↗
Stock Splits
No stock splits in BIOA's price history.

